| ACLARIS THERAPEUTICS DL 1 |
| USA |
| Gesundheit |
| US00461U1051 / A1412H |
| 8AT (Frankfurt) / ACRS (NASDAQ) |
| FRA:8AT, ETR:8AT, 8AT:GR, NASDAQ:ACRS |
| - |
| https://www.aclaristx.com.. |
|
Aclaris Therapeutics, Inc., a clinical-stage bioph..
>Volltext.. |
| 296.45 Mio. EUR |
| 216.53 Mio. EUR |
| 13.42 Mio. EUR |
| -55.33 Mio. EUR |
| -120.77 Mio. EUR |
| -1.18 EUR |
| 1.91 Mio. EUR |
| 21.53 Mio. EUR |
| -36.58 Mio. EUR |
| 3.74 |
| -44.84% |
| -263.29% |
| - |
| - |
| - |
| - |
| ACLARIS |
| 17.12.25 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|